Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. (ACUR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
acur · stock forecast · 3 analysts (3M) · FMP · updated Apr 30, 2024
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.00
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.00 | ↓ 0.60% |
1-day model range: $0–$0. Peak: $0 (-0.60%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · ACUR · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2016-03-11 | Roth Capital | Maintains | Buy→Buy |
| 2015-02-27 | MLV & Co. | Upgrade ↑ | Hold→Buy |
| 2014-05-28 | MLV & Co. | Downgrade ↓ | Buy→Hold |
| 2013-08-14 | McNicoll Lewis Vlak | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Acura Pharmaceuticals, Inc. (ACUR) stock. Of the recent 4 rating actions, 1 were upgrades and 1 were downgrades. 3 analysts currently cover ACUR.
Analyst Recommendation Trends
ACUR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$10M
↑ 14.4% YoY
Revenue Next Year
$9M
↓ 6.5% YoY
EPS This Year
$-0.77
EPS Next Year
$-0.72
↓ 5.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast ACUR EPS of $-0.77 for the current fiscal year, based on estimates from 12 analysts. The ACUR revenue forecast is $10M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ACUR stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ACUR price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The ACUR short-term stock prediction for tomorrow is $0.00 (-0.60%).
Acura Pharmaceuticals, Inc. trades on OTC under the ticker ACUR. The ACUR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
ACUR forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month ACUR price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.